Exhibit 99. 1 PURE Bioscience Reports Fiscal 2026 Financial Results El CAJON, CA - PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company,” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal year ended July 31, 2026. Summary of Results - Year-End Operations Net product sales were $2,315,000 and $2,198,000 for the fiscal years ended July 31, 2026 and 2025, respectively. The $117,000 increase was attributable to increased sales across our end-user network. Net loss for the fiscal year ended July 31, 2026 was ($2.5 million), compared to ($2.4 million) for the fiscal year ended July 31, 2025. During the prior fiscal year, net loss was offset by $175,000 received from the U.S. Government’s Employee Retention Tax Credit Program. Net loss, excluding share-based compensation, was ($2.3 million) for the fiscal years ended July 31, 2026 and 2025, respectively. Net loss per share was ($0.02) for the fiscal years ended July 31, 2026 and 2025, respectively. Net cash used in operations for the fiscal year ended July 31, 2026 was ($1.97 million), compared to ($2.0 mi…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
PURE Bioscience, Inc.
PUREOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On October 29, 2026, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal year ended July 31, 2026 and related information. A copy of the press release is attached as Exhibit 99.1.…
Press release in this filing
PURE Bioscience Reports Fiscal 2026 Financial Results →Recent company filings
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02. Results of Operations and Financial Condition.
On
October 29, 2026, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal
year ended July 31, 2026 and related information. A copy of the press release is attached as Exhibit 99.1.
The
information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated
by reference into any registration statement or other document filed with the Securities and Exchange Commission.